A phase 2 trial of aderbasib for breast cancer.

Trial Profile

A phase 2 trial of aderbasib for breast cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Aderbasib (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 11 Feb 2016 Based on the interim results of JANUS 1 and the phase 2 sub-study in patients with metastatic colorectal cancer and CRP, ongoing Incyte-sponsored trials of ruxolitinib in solid tumors will be discontinued, including the phase 3 JANUS 2 study in pancreatic cancer, the Phase 2 sub-study in patients with metastatic colorectal cancer and low CRP, and the phase 2 studies in breast and lung cancer, according to an Incyte Corporation media release.
    • 02 Nov 2007 Status changed from planning to recruiting.
    • 02 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top